Next-generation obesity company with potential best- and first-in-class assets launched by Versant Ventures Emerges from stealth with $30 million in Series A financing and a strategic collaboration
Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led b.